Page 16 - Genmark Diagnostics News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Roche will buy GenMark Diagnostics, a U.S.-based maker of molecular diagnostic tests in a US$1.8 billion deal, the Swiss pharmaceuticals ...

Roche said it is offering $24.05 a share for GenMark, a premium of some 43 percent to its last quoted share price on February 10.

European stocks ended flat on Monday, with declines led by financial and mining stocks, while gains in betting firm Flutter Entertainment and optimism about a strong economic rebound helped limit losses.

Roche to Buy Covid Test Maker GenMark for $1.8 Billion This content was published on March 15, 2021 - 08:19 March 15, 2021 - 08:19 (Bloomberg) -- Roche Holding AG agreed to buy GenMark Diagnostics Inc. for about $1.8 billion to gain a provider of fast tests for infectious diseases, including Covid-19. The Swiss drugmaker will pay $24.05 a share in cash, it said in a statement Monday. That’s 30% more than Friday’s closing price. The boards of both companies approved the transaction. GenMark’s tests can detect multiple pathogens from a single patient sample. The pandemic has fueled demand...

Roche Holding AG (SWX: RO) said on Monday that it will buy GenMark Diagnostics (NASDAQ: GNMK) for £1.29 billion. The all-cash deal translates to £17.25 per share. To fully acquire the United States-based molecular diagnostic tests maker, Roche intends to launch a tender offer soon. Roche shares jumped roughly 1% in premarket trading on Monday. […]